Open AccessHER2/neu May Not Be an Interesting Target in Biliary Cancers: Results of an Early Phase II Study with Lapatinib
Author(s) -
Joshua R. Peck,
Lai Wei,
Mark M. Zalupski,
Bert H. O’Neil,
Miguel Villalona Calero,
Tanios BekaiiSaab
Publication year - 2012
Publication title -
oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.987
H-Index - 98
eISSN - 1423-0232
pISSN - 0030-2414
DOI - 10.1159/000336488
Subject(s) - lapatinib , medicine , gastroenterology , oncology , epidermal growth factor receptor , population , trastuzumab , chemotherapy , cancer , breast cancer , environmental health
Biliary cancers (BCs) respond poorly to chemotherapy. Lapatinib is a dual inhibitor of epidermal growth factor receptor (EGFR) and HER2/neu, both implicated in cholangiocarcinogenesis. This trial was designed to determine the safety and efficacy of lapatinib in BC.